Our CEO, Dr. Tuvik Beker, will be presenting a Showcase at PMWC 2025 discussing the exciting progress Pangea Biomed has been making in unlocking the promise and hope of precision oncology for patients that need it most. He will discuss how ENLIGHT is empowering oncologists to make more informed treatment decisions, leading to better patient outcomes, and how ENLIGHT is accelerating the development of targeted cancer therapies, bringing new hope to patients faster. He will also be talking about what lies ahead: recent validations of ENLIGHT-DP (our next-generation predictive biomarker based on histopathology slide images), our regulatory roadmap, and our recent commercial launch.

Our COO, Emmanuel Elalouf, attended BIO-Europe Spring 2024 to connect with leading pharma executives.

Our CEO Tuvik Beker and COO Emmanuel Elaouf attended the conference to meet with industry leaders and executives.

Our CEO Tuvik Beker presented a talk titled, “ENLIGHT: Predicting response to cancer therapy based on gene expression patterns from RNAseq or H&E slides.”

CTO Ranit Aharonov presented a presentation titled, “Prediction of Cancer Treatment Response from Histopathology Images Through Imputed Transcriptomics.”

Our CEO Tuvik Beker and Head of Research Gal Dinstag attended AACR to connect with leading oncology executives. Gal presented two posters on ENLIGHT and the ENLIGHT-DP framework.

Our CEO Tuvik Beker gave a presentation on ENLIGHT at Biomed Israel 2023.

CEO Tuvik Beker gave a presentation about ENLIGHT at the ARC summit in Tel Aviv, Israel.

COO Emmanuel Elalouf attended the Bio International Convention in Boston to meet with industry leaders and executives.

Our CTO Ranit Aharonov and COO Emmanuel Elalouf attended ASCO 2023. Ranit presented two posters: one on our ENLIGHT technology and the other on the ENLIGHT-DP framework.

Pangea presented a poster on the predictiveness of ENLIGHT technology.